253 related articles for article (PubMed ID: 30450942)
1. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
Brown CC; Manis MM; Bohm NM; Curry SR
Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
[TBL] [Abstract][Full Text] [Related]
2. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
4. Oral Vancomycin as Secondary Prophylaxis for
Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
[TBL] [Abstract][Full Text] [Related]
5. Oral vancomycin prophylaxis for the prevention of
Babar S; El Kurdi B; El Iskandarani M; Haddad I; Imam Z; Alomari M; Myers J; Moorman J
Infect Control Hosp Epidemiol; 2020 Nov; 41(11):1302-1309. PubMed ID: 32594929
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
Knight EM; Schiller DS; Fulman MK; Rastogi R
J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
8. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent
Chang LL; Allegretti J; Skinner AM; Dubberke ER
N Engl J Med; 2023 Feb; 388(7):654-656. PubMed ID: 36791167
[No Abstract] [Full Text] [Related]
9. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
[TBL] [Abstract][Full Text] [Related]
10. Oral vancomycin prophylaxis against recurrent
Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
[TBL] [Abstract][Full Text] [Related]
11. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection.
Zhang K; Beckett P; Abouanaser S; Stankus V; Lee C; Smieja M
BMC Infect Dis; 2019 Jan; 19(1):51. PubMed ID: 30642269
[TBL] [Abstract][Full Text] [Related]
12. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
[TBL] [Abstract][Full Text] [Related]
14. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant.
Altemeier OJ; Konrardy KT
Transpl Infect Dis; 2022 Apr; 24(2):e13790. PubMed ID: 35014136
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients.
Splinter LE; Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson GE; Saddler CM; Smith JA; Safdar N; Redfield RR
Ann Pharmacother; 2018 Feb; 52(2):113-119. PubMed ID: 28844154
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA
Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection.
O'Donnell JN; Novak GM; Bratek BR; Singh G; Duru OO; Mitchell CL; Roddy KM; Bidell MR
Int J Antimicrob Agents; 2021 Apr; 57(4):106311. PubMed ID: 33621602
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
[TBL] [Abstract][Full Text] [Related]
20. Review of high dose vancomycin in the treatment of
Bader MS; Hawboldt J; Main C; Mertz D; Loeb M; Farrell A; Joyce J
Infect Dis (Lond); 2020; 52(12):847-857. PubMed ID: 32744879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
